


KISQALI® Specialty Pharmacy ribociclib 200 mg Network Update **Network Update**

Novartis maintains an unwavering commitment to facilitating access to care for patients. As a part of this commitment, effective November 1, 2025, the specialty pharmacy network for KISQALI will be updated to provide options to meet the different needs of health care professionals (HCPs) and patients.



Novartis Patient Support™

Support is available to facilitate transitioning patients to help ensure no gap in treatment.

The Novartis Patient Support team offers dedicated resources and support designed specifically to help make the transition process easier, including:



Insurance benefits verification to determine if there is a payer-mandated specialty pharmacy and support if a prior authorization or appeal is needed



Access to programs that assist eligible patients if there is an issue or delay transitioning the prescription before the next refill is due



Assistance confirming your eligible patients with private insurance are enrolled in savings programs as well as ensuring their new specialty pharmacy has relevant information to apply savings



Single point of contact for both you and your patient throughout the process

Get your patients started with guidance along the way.



↓ Download the KISQALI Start Form

Questions?

For more information, call Novartis Patient Support at 1-866-433-8000. Monday to Friday 8:00 AM to 8:00 PM ET. excluding holidays.

FDA, US Food and Drug Administration.

*The Bridge Program applies to KISQALI and the KISQALI FEMARA® (letrozole) Co-Pack only. Eligible patients must have private insurance, a valid prescription for KISQALI or the KISQALI FEMARA Co-Pack, and a denial of insurance coverage based on a prior authorization requirement. Program requires the submission of a prior authorization and/or appeal of the coverage denial within the first 90 days of enrollment to remain eligible. Program provides KISQALI for free to eligible patients for up to 5 months, or until they receive insurance coverage approval, whichever occurs earlier. A valid prescription consistent with FDA-approved labeling is required. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Patients may be asked to reverify insurance coverage status during the course of the program.

No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Additional limitations may apply. Novartis Pharmaceuticals Corporation reserves the right to rescind, revoke, or amend this Program without notice.

About the Updated Specialty Pharmacy Network for KISQALI

In addition to hospital outpatient pharmacies or outpatient clinic/practice pharmacies, as of October 24, 2025, the intended network will include the full-service specialty pharmacies listed below.* Novartis may modify this network at any time without notice.

PHARMACY	PHONE	FAX	HOURS OF OPERATION
AcariaHealth Specialty Pharmacy	1-800-511-5144	1-877-541-1503	24/7
Accredo Specialty Pharmacy	1-877-732-3431	1-888-302-1028	24/7
Walgreens Specialty Pharmacy	1-888-347-3416	1-877-231-8302	8 AM to 8 PM ET, Mon to Fri; 8 AM to 5 PM ET, Sat
BioPlus Specialty Pharmacy	1-866-514-8082	1-800-269-5493	7 AM to 10 PM ET, Mon to Sun Clinical consult and support 24/7
Biologics by McKesson	1-800-850-4306	1-800-823-4506	8 AM to 8 PM ET, Mon to Fri Registered pharmacists available 24/7
CVS Specialty Pharmacy	1-855-539-4712	1-888-435-1256	8 AM to 8 PM ET, Mon to Fri
CenterWell Specialty Pharmacy	1-800-486-2668	1-877-405-7940	8 ам to 11 рм ET, Mon to Fri; 8 ам to 6:30 рм ET, Sat
Onco360 Oncology Pharmacy	1-877-662-6633	1-877-662-6355	24/7
Optum Specialty Pharmacy	1-877-445-6874	1-877-342-4596	24/7

^{*}Novartis does not recommend or require the use of any particular pharmacy. Please refer to the patient's health plan for requirements regarding use of particular specialty pharmacies.

Facilitating Patient Access to KISQALI for New and Transferring Patients

The updated specialty pharmacy network will coordinate with pharmacies outside of the network to transfer patients and maintain continuity of their KISQALI treatment.

TRANSFERRING PATIENTS

 The network specialty pharmacy will initiate the prescription transfer for KISQALI and fill subsequent prescriptions or reach out to the HCP for a new prescription. The network specialty pharmacy will contact the patient to coordinate KISQALI delivery once it is filled

PATIENTS NEW TO THERAPY

- HCP may send the KISQALI prescription to a network specialty pharmacy, hospital outpatient pharmacy, or outpatient clinic/practice pharmacy
- Please refer to patient's health plan for requirements regarding use of particular specialty pharmacies

10/25



